Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 3 2000
Play
Audio Below:
Well,
perhaps for the same reason that I drink Coke and not Pepsi, I have
written very few prescriptions for letrozole and generally when
you’re the first player on the block, people develop a confidence
and comfort with you. Arimidex is a drug that I am entirely comfortable
with, that I think is exceedingly safe and quite effective and I
have no great compelling reasons to drink Pepsi so to speak.
With
regards to the newest player on the block, exemestane or Aromacin,
I think we just lack sufficient data to know how its going to fit
into the algorithm. The uniqueness perhaps of its mechanism of action
– it’s perhaps more of an activator of aromatase –
is intriguing. But the relative roles of these agents as mono-therapy
and certainly in combination, certainly need to be explored.
